Glimepiride; pioglitazone hydrochloride - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for glimepiride; pioglitazone hydrochloride and what is the scope of freedom to operate?
Glimepiride; pioglitazone hydrochloride
is the generic ingredient in two branded drugs marketed by Takeda Pharms Usa and Sandoz, and is included in two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Glimepiride; pioglitazone hydrochloride has fifty-nine patent family members in thirty-one countries.
Three suppliers are listed for this compound.
Summary for glimepiride; pioglitazone hydrochloride
International Patents: | 59 |
US Patents: | 2 |
Tradenames: | 2 |
Applicants: | 2 |
NDAs: | 2 |
Finished Product Suppliers / Packagers: | 3 |
Clinical Trials: | 20 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for glimepiride; pioglitazone hydrochloride |
DailyMed Link: | glimepiride; pioglitazone hydrochloride at DailyMed |
Recent Clinical Trials for glimepiride; pioglitazone hydrochloride
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Seoul National University Hospital | Phase 4 |
Kanazawa University | Phase 4 |
Kowa Company, Ltd. | Phase 4 |
See all glimepiride; pioglitazone hydrochloride clinical trials
Pharmacology for glimepiride; pioglitazone hydrochloride
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
DUETACT | Tablets | glimepiride; pioglitazone hydrochloride | 30 mg/2 mg and 30 mg/4 mg | 021925 | 1 | 2009-12-22 |
US Patents and Regulatory Information for glimepiride; pioglitazone hydrochloride
Expired US Patents for glimepiride; pioglitazone hydrochloride
International Patents for glimepiride; pioglitazone hydrochloride
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
European Patent Office | 1677792 | PREPARATION SOLIDE COMPRENANT DE LA PIOGLITAZONE, DU GLIMEPIRIDE ET UN ESTER D'ACIDE GRAS DE POLYOXYETHYLENE SORBITAN (SOLID PREPARATION COMPRISING PIOGLITAZONE, GLIMEPIRIDE AND A POLYOXYETHYLENE SORBITAN FATTY ACID ESTER) | ⤷ Sign Up |
South Africa | 200602056 | Solid preparation comprising an insulin sensitizer, an insulin secretagogue and a polyoxyethylene sorbitan fatty acid ester | ⤷ Sign Up |
South Africa | 200805147 | Solid preparation | ⤷ Sign Up |
Costa Rica | 10032 | PREPARACIÓN SÓLIDA | ⤷ Sign Up |
Peru | 20050923 | COMPOSICION SOLIDA QUE COMPRENDE UN SENSIBILIZADOR DE INSULINA, UN SECRETAGOGO DE INSULINA Y UN ESTER DE ACIDOS GRASOS | ⤷ Sign Up |
New Zealand | 546337 | Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80 | ⤷ Sign Up |
Norway | 340294 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.